IRUS Total

11C-PE2I and 18F-DOPA PET for assessing progression rate in Parkinson’s: a longitudinal study

File Description SizeFormat 
Comparison_of_18F-DOPA_and_11C-PE2I_PET_CLEAN.docxAccepted version232.35 kBMicrosoft WordView/Open
Title: 11C-PE2I and 18F-DOPA PET for assessing progression rate in Parkinson’s: a longitudinal study
Authors: Li, W
Lao-Kaim, N
Roussakis, AA
Martin Bastida, A
Valle Guzman, N
Paul, G
Loane, C
Widner, H
Politis, M
Foltynie, T
Barker, R
Piccini, P
Item Type: Journal Article
Abstract: Background 18F-dopa PET measuring aromatic l-amino acid decarboxylase activity is regarded as the gold standard for evaluating dopaminergic function in Parkinson's disease. Radioligands for dopamine transporters are also used in clinical trials and for confirming PD diagnosis. Currently, it is not clear which imaging marker is more reliable for assessing clinical severity and rate of progression. The objective of this study was to directly compare 18F-dopa with the highly selective dopamine transporter radioligand 11C-PE2I for the assessment of motor severity and rate of progression in PD. Methods Thirty-three mild-moderate PD patients underwent 18F-dopa and 11C-PE2I PET at baseline. Twenty-three were followed up for 18.8 ± 3.4 months. Results Standard multiple regression at baseline indicated that 11C-PE2I BPND predicted UPDRS-III and bradykinesia-rigidity scores (P < 0.05), whereas 18F-dopa Ki did not make significant unique explanatory contributions. Voxel-wise analysis showed negative correlations between 11C-PE2I BPND and motor severity across the whole striatum bilaterally. 18F-Dopa Ki clusters were restricted to the most affected putamen and caudate. Longitudinally, negative correlations were found between striatal Δ11C-PE2I BPND, ΔUPDRS-III, and Δbradykinesia-rigidity, whereas no significant associations were found for Δ18F-dopa Ki. One cluster in the most affected putamen was identified in the longitudinal voxel-wise analysis showing a negative relationship between Δ11C-PE2I BPND and Δbradykinesia-rigidity. Conclusions Striatal 11C-PE2I appears to show greater sensitivity for detecting differences in motor severity than 18F-dopa. Furthermore, dopamine transporter decline is closely associated with motor progression over time, whereas no such relationship was found with aromatic l-amino acid decarboxylase. 11C-PE2I may be more effective for evaluating the efficacy of neuroprotective treatments in PD. © 2017 International Parkinson and Movement Disorder Society
Issue Date: 30-Oct-2017
Date of Acceptance: 31-Aug-2017
URI: http://hdl.handle.net/10044/1/50554
DOI: https://dx.doi.org/10.1002/mds.27183
ISSN: 0885-3185
Publisher: Wiley
Start Page: 117
End Page: 127
Journal / Book Title: Movement Disorders
Volume: 33
Issue: 1
Copyright Statement: This is the peer reviewed version of the following article: Li, W., Lao-Kaim, N. P., Roussakis, A. A., Martín-Bastida, A., Valle-Guzman, N., Paul, G., Loane, C., Widner, H., Politis, M., Foltynie, T., Barker, R. A. and Piccini, P. (2018), 11C-PE2I and 18F-Dopa PET for assessing progression rate in Parkinson's: A longitudinal study. Mov Disord., 33: 117–127. , which has been published in final form at https://dx.doi.org/10.1002/mds.27183.  This article may be used for non-commercial purposes in accordance With Wiley Terms and Conditions for self-archiving.
Sponsor/Funder: Commission of the European Communities
Funder's Grant Number: 242003
Keywords: 11C-PE2I
Parkinson's disease
aromatic l-amino acid decarboxylase
dopamine transporter
1103 Clinical Sciences
1106 Human Movement And Sports Science
1702 Cognitive Science
Neurology & Neurosurgery
Publication Status: Published
Appears in Collections:Department of Medicine (up to 2019)